Logo image of STAA

STAAR SURGICAL CO (STAA) Stock Fundamental Analysis

NASDAQ:STAA - Nasdaq - US8523123052 - Common Stock - Currency: USD

16.87  +0.02 (+0.12%)

After market: 16.8 -0.07 (-0.41%)

Fundamental Rating

5

Taking everything into account, STAA scores 5 out of 10 in our fundamental rating. STAA was compared to 190 industry peers in the Health Care Equipment & Supplies industry. STAA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STAA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

STAA had positive earnings in the past year.
STAA had a positive operating cash flow in the past year.
Of the past 5 years STAA 4 years were profitable.
Each year in the past 5 years STAA had a positive operating cash flow.
STAA Yearly Net Income VS EBIT VS OCF VS FCFSTAA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

The Return On Assets of STAA (-3.97%) is better than 64.89% of its industry peers.
Looking at the Return On Equity, with a value of -5.09%, STAA is in the better half of the industry, outperforming 68.09% of the companies in the same industry.
Industry RankSector Rank
ROA -3.97%
ROE -5.09%
ROIC N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
STAA Yearly ROA, ROE, ROICSTAA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of STAA (76.32%) is better than 88.30% of its industry peers.
In the last couple of years the Gross Margin of STAA has remained more or less at the same level.
STAA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
STAA Yearly Profit, Operating, Gross MarginsSTAA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

STAA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STAA has been increased compared to 1 year ago.
The number of shares outstanding for STAA has been increased compared to 5 years ago.
STAA has a better debt/assets ratio than last year.
STAA Yearly Shares OutstandingSTAA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STAA Yearly Total Debt VS Total AssetsSTAA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 5.50 indicates that STAA is not in any danger for bankruptcy at the moment.
STAA's Altman-Z score of 5.50 is amongst the best of the industry. STAA outperforms 80.32% of its industry peers.
There is no outstanding debt for STAA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.5
ROIC/WACCN/A
WACC9.06%
STAA Yearly LT Debt VS Equity VS FCFSTAA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.23 indicates that STAA has no problem at all paying its short term obligations.
STAA's Current ratio of 5.23 is fine compared to the rest of the industry. STAA outperforms 77.66% of its industry peers.
STAA has a Quick Ratio of 4.62. This indicates that STAA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.62, STAA is doing good in the industry, outperforming 79.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.23
Quick Ratio 4.62
STAA Yearly Current Assets VS Current LiabilitesSTAA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

STAA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.00%.
Measured over the past 5 years, STAA shows a small growth in Earnings Per Share. The EPS has been growing by 7.49% on average per year.
STAA shows a decrease in Revenue. In the last year, the revenue decreased by -2.64%.
STAA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.88% yearly.
EPS 1Y (TTM)-45%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-484.62%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-35.82%

3.2 Future

Based on estimates for the next years, STAA will show a very strong growth in Earnings Per Share. The EPS will grow by 59.43% on average per year.
Based on estimates for the next years, STAA will show a quite strong growth in Revenue. The Revenue will grow by 17.55% on average per year.
EPS Next Y-373.06%
EPS Next 2Y-18.21%
EPS Next 3Y4.89%
EPS Next 5Y59.43%
Revenue Next Year-23.81%
Revenue Next 2Y-2.07%
Revenue Next 3Y-1.26%
Revenue Next 5Y17.55%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
STAA Yearly Revenue VS EstimatesSTAA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
STAA Yearly EPS VS EstimatesSTAA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 51.12 indicates a quite expensive valuation of STAA.
68.09% of the companies in the same industry are more expensive than STAA, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 29.63. STAA is valued rather expensively when compared to this.
STAA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 51.12
Fwd PE N/A
STAA Price Earnings VS Forward Price EarningsSTAA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STAA Per share dataSTAA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)6.83
EPS Next 2Y-18.21%
EPS Next 3Y4.89%

More info and screens

0

5. Dividend

5.1 Amount

STAA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STAAR SURGICAL CO

NASDAQ:STAA (2/21/2025, 8:00:01 PM)

After market: 16.8 -0.07 (-0.41%)

16.87

+0.02 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners100.92%
Inst Owner Change-95.7%
Ins Owners0.42%
Ins Owner Change4.08%
Market Cap831.35M
Analysts79
Price Target22.51 (33.43%)
Short Float %8.04%
Short Ratio4.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1639.16%
Min EPS beat(2)-3398.76%
Max EPS beat(2)120.44%
EPS beat(4)3
Avg EPS beat(4)-787.98%
Min EPS beat(4)-3398.76%
Max EPS beat(4)120.44%
EPS beat(8)5
Avg EPS beat(8)-382.88%
EPS beat(12)9
Avg EPS beat(12)-223.81%
EPS beat(16)12
Avg EPS beat(16)-47.33%
Revenue beat(2)0
Avg Revenue beat(2)-18.98%
Min Revenue beat(2)-37.91%
Max Revenue beat(2)-0.06%
Revenue beat(4)2
Avg Revenue beat(4)-8.86%
Min Revenue beat(4)-37.91%
Max Revenue beat(4)1.96%
Revenue beat(8)3
Avg Revenue beat(8)-4.18%
Revenue beat(12)4
Avg Revenue beat(12)-2.88%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)-47.89%
PT rev (3m)-48.66%
EPS NQ rev (1m)-280.73%
EPS NQ rev (3m)-248.45%
EPS NY rev (1m)-210.1%
EPS NY rev (3m)-211.24%
Revenue NQ rev (1m)-38.13%
Revenue NQ rev (3m)-40.13%
Revenue NY rev (1m)-31.08%
Revenue NY rev (3m)-32.23%
Valuation
Industry RankSector Rank
PE 51.12
Fwd PE N/A
P/S 2.65
P/FCF N/A
P/OCF 52.87
P/B 2.09
P/tB 2.1
EV/EBITDA N/A
EPS(TTM)0.33
EY1.96%
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.32
OCFY1.89%
SpS6.37
BVpS8.06
TBVpS8.03
PEG (NY)N/A
PEG (5Y)6.83
Profitability
Industry RankSector Rank
ROA -3.97%
ROE -5.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.32%
FCFM N/A
ROA(3y)3.25%
ROA(5y)3.83%
ROE(3y)4.04%
ROE(5y)4.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.47%
F-Score3
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 339.49%
Cap/Sales 7.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.23
Quick Ratio 4.62
Altman-Z 5.5
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)365.33%
Cap/Depr(5y)348.39%
Cap/Sales(3y)6.49%
Cap/Sales(5y)6.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45%
EPS 3Y-12.35%
EPS 5Y7.49%
EPS Q2Q%-484.62%
EPS Next Y-373.06%
EPS Next 2Y-18.21%
EPS Next 3Y4.89%
EPS Next 5Y59.43%
Revenue 1Y (TTM)-2.64%
Revenue growth 3Y10.84%
Revenue growth 5Y15.88%
Sales Q2Q%-35.82%
Revenue Next Year-23.81%
Revenue Next 2Y-2.07%
Revenue Next 3Y-1.26%
Revenue Next 5Y17.55%
EBIT growth 1Y-144.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year677.78%
EBIT Next 3Y163.91%
EBIT Next 5Y119.91%
FCF growth 1Y-113.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.75%
OCF growth 3Y-29.01%
OCF growth 5Y-9.43%